Introduction
============

Thoroughly performed pre-surgery diagnostics are essential for all disease management decisions. In breast cancer patients, axillary lymph node status is of paramount importance as a prognostic factor and predictor of survival[@b1-bcbcr-7-2013-035] as there is a direct correlation between primary tumor size and risk of axillary lymph node metastases as well as between the number of affected axillary lymph nodes and the recurrence risk.[@b2-bcbcr-7-2013-035]

Today, sentinel node biopsy and/or conventional axillary lymph node dissection (ALND, level I + II) are considered the gold standard for nodal staging.[@b3-bcbcr-7-2013-035] While for clinically node-positive patients ALND is the standard of care, clinically node-negative patients need to be first evaluated by sentinel node biopsy (SLNB). In case of identification of affected lymph nodes, an ALND is recommended in order to avoid local tumor spread.[@b3-bcbcr-7-2013-035] In order to shorten surgery time, attempts should be undertaken to apply non-invasive techniques for nodal staging, such as axillary ultrasound.

Ultrasound has been shown to be a useful tool in the diagnostic armamentarium for nodal staging.[@b4-bcbcr-7-2013-035] Vaidya et al reported the combination of clinical palpation complemented by axillary ultrasound to increase the sensitivity for axillary lymph node detection from 70% to 82%.[@b5-bcbcr-7-2013-035] However, accuracy strongly depends on technical skills and experience of the operator.[@b6-bcbcr-7-2013-035] In our study we aimed to confirm this finding with the data generated in our population by our staff.

Sensitivity achieved by ultrasound, however, is inferior to those achieved by surgical procedures although fine needle aspiration cytology or biopsy might improve US diagnosis. In the study reported, here we attempted to identify clinical/histopathological factors that might impact diagnostic performance of the combination of palpation and axillary ultrasound.

Materials and Methods
=====================

Study design
------------

We conducted a retrospective chart analysis on women with primary breast cancer who were treated at the department of OB/GYN at Saarland University Hospital, 66421 Homburg/Saar, Germany over a period of two years. Our clinic is a certified breast cancer center that strictly follows the international diagnostic and therapeutic guidelines postulated by the European Society of Mastology, so called EUSOMA criteria.[@b7-bcbcr-7-2013-035] According to the guidelines of the Helsinki Declaration, ethics approval was not necessary for this retrospective analysis.

Study population
----------------

Datasets of women of all ages presenting a primary invasive breast cancer stage pT1a or higher were eligible for inclusion. Only complete cases that included a thoroughly documented medical history, records of clinical palpation findings, axillary ultrasound outcomes, and histopathological results of primary tumor and axillary lymph nodes were accepted. Patients, who had performed their pre-surgery diagnostic procedures externally or who presented non-invasive tumors (DCIS, CLIS) or a recurrent disease, were excluded.

Study assessments
-----------------

We used a special template for recording medical history comprising age, height, weight, family history, parity, age at first delivery, and duration of lactation. The clinical examination included inspection and palpation of both breasts and armpits providing the clinical nodal status.

Mammographies were performed at our local department of radiology and evaluated by at least two physicians (four-eyes-principle).

The axillary ultrasound examinations were carried out by specially trained gynecologists using a Hitachi EUB-8000 with a linear 13 MHz probe. The patient was lying in supine position with widely angled arms above the head. Breasts and armpits were studied in transversal and sagittal planes, with special focus on the region around the axillary vessels and the region above and below the collarbones. Lymph nodes size \> 2 cm in diameter, round shape, Solbiati-Index \< 2 (longitudinal-transverse diameter ratio), loss of central echo, disrupted lymph node capsule, and increased intranodal vascularization or atypical vessels were considered as morphologic ultrasound criteria of lymph node malignancy. The histopathological assessments were done by the in-house department of pathology (Dept. of Pathology).

Statistical methods
-------------------

Continuous variables are presented as mean ± standard deviation (SD). For categorical variables frequency resp. contingency tables were calculated. In case of missing data, the calculations were based on the available data set. We calculated sensitivity, specificity, ppv, and npv for the two diagnostic methods (palpation alone and palpation plus axillary ultrasound).

We used Pearson's Chi-Square-test resp. Fisher's exact test to compare sensitivity and specificity depending on certain clinical and pathological factors. A *P*-value \< 0.05 was considered as statistically significant.

All data analyses were performed with SPSS™ (SPSS Inc. Chicago, Illinois, Version 17).

Results
=======

We enrolled a total of 172 patients in our study. The demographic data of our population is shown in [Table 1](#t1-bcbcr-7-2013-035){ref-type="table"}. The majority were postmenopausal women (mean age 58.8 ± 12.87 years) and slightly overweight (BMI 27.2 ± 5.0 kg/m^2^). Nulliparous women were a minority (11%) and two thirds (66%) had a negative family history with respect to breast cancer.

Tumor characteristics are shown in [Table 2](#t2-bcbcr-7-2013-035){ref-type="table"}. Almost half of the tumors (44.1%) were in the upper lateral quadrants (right or left) with a mean size of 21.3 ± 1.73 mm. One third of the patients (n = 54; 31.4%) were clinically nodal positive, while 77 patients (45%) were histopathologically nodal positive. Forty-six patients of these 77 nodal positive patients were classified as pN1 (including 6 microscopic pN1). A total of 17 women (9.9%) already had distant metastases. 101 patients (58.7%) had the disease staging pT1.

The diagnostic performance of the axillary palpation alone and the combination of palpation plus axillary ultrasound are depicted in [Figure 1](#f1-bcbcr-7-2013-035){ref-type="fig"}. The palpation alone had a low sensitivity of 31.6% while both modalities combined reached 58%, a statistically significant increase in diagnostic efficacy (*P* \< 0.01). While specificity and ppv did not improve with adding axillary ultrasound, npv increased from 63.4% to 73%, using both modalities.

Sensitivity and specificity of palpation in combination with ultrasound were unaffected by parameters like age at diagnosis, BMI, tumor localization, multicentricity, carcinoma type, grading hormone receptor status, HER2/neu status, and presence or absence of lymphangiosis carcinomatosa. But four clinical/pathological factors affected significantly diagnostic performance: tumor size (impact on specificity only), palpable axillary lymph nodes (sensitivity and specificity), the number of affected lymph nodes (sensitivity only), and presence of distant metastases (M1) (sensitivity only) ([Table 3](#t3-bcbcr-7-2013-035){ref-type="table"}).

While for tumor size, no clear-cut trend depending on size categories could be detected, positive or negative axillary palpation significantly increased sensitivity and specificity, respectively. With increasing numbers of affected lymph nodes, sensitivity of ultrasound increased (*P* \< 0.01). Regarding presence or absence of distant metastases (M0/1), all women with metastases (pM1 or cM1) had positive lymph nodes ([Table 4](#t4-bcbcr-7-2013-035){ref-type="table"}).

Discussion
==========

We conducted this retrospective chart analysis to assess the diagnostic value of pre-surgery axillary ultrasound for nodal staging in breast cancer patients and to identify clinical/pathological factors impacting diagnostic performance. Limitations of this study include the retrospective study design, a somewhat small sample size, as well as the inter-reader variability in ultrasound results due to three participating gynecologists. In addition, the study population showing relatively advanced tumor stages and large primary tumors might not be representative for other centers.

Our results show that clinical palpation alone had a low sensitivity of 31.6% while when combined with axillary ultrasound, both modalities together reached 58%, a statistically significant increase in sensitivity (*P* \< 0.001). Specificity remained high at 91.6% while npv increased from 63.4% to 73%, using both diagnostic modalities. In comparison, our sensitivity was in the range of data reported by Jung et al[@b4-bcbcr-7-2013-035] (sensitivity of 54%), Garcia-Ortega et al (63%),[@b8-bcbcr-7-2013-035] and Mills et al (59%),[@b9-bcbcr-7-2013-035] but somewhat lower than findings reported by other groups. In particular Vaidya et al reported 82%,[@b5-bcbcr-7-2013-035] Kebudi et al 79.1%,[@b10-bcbcr-7-2013-035] Strauss et al 90%,[@b11-bcbcr-7-2013-035] Yang et al 841%,[@b12-bcbcr-7-2013-035] and Bonnema et al 87%.[@b13-bcbcr-7-2013-035] However, specificity, ppv and npv were almost in the same range.[@b4-bcbcr-7-2013-035],[@b5-bcbcr-7-2013-035],[@b12-bcbcr-7-2013-035]--[@b15-bcbcr-7-2013-035] Since our study population is very typical for patients with first diagnosis of breast cancer, the differences might be explained by the fact that axillary ultrasound examinations were done by a team of 3 specifically trained gynecologists during their residency and not by one highly specialized individual in a prospective study setting, thus reflecting day-to-day reality in most hospitals and private practices. In general, higher sensitivity due to axillary ultrasound helps to reduce surgery time as patients with positive axillary lymph nodes directly get an ALND, without preceding SLNB. Higher specificity might help patients with negative lymph nodes, as an ALND can be avoided if a negative nodal status can be confirmed by a SLNB.[@b11-bcbcr-7-2013-035],[@b16-bcbcr-7-2013-035],[@b17-bcbcr-7-2013-035]

We could show that clinical/pathological parameters like age at diagnosis, BMI, tumor localization, multi-centricity, carcinoma type, grading, hormone receptor status, HER2/neu status, and presence or absence of lymphangiosis carcinomatosa had no impact on sensitivity and specificity of palpation plus axillary ultrasound. This result is in line with the findings of Bedrosian et al, who conducted a very similar study on 208 patients.[@b14-bcbcr-7-2013-035] In contrast to Bedrosian et al, we could provide evidence for four factors increasing either sensitivity (number of affected lymph nodes), specificity (tumor size), or both (axillary palpation, distant metastases). It appears quite conclusive that sensitivity increases parallel to the number of affected lymph nodes. Unfortunately, we were not able to demonstrate a clear-cut relationship between tumor size and sensitivity: While sensitivity increased from the tumor size category \< 2 cm (46.2%) to 2.0--2.9 cm (66.7%), no further increase for larger tumors could be detected. This is probably due to the small sample size of 10, 5, and 11 patients in the tumor categories of 3.0--3.9 cm, 4.0--4.0 cm and \>5 cm, respectively ([Table 4](#t4-bcbcr-7-2013-035){ref-type="table"}). It is noteworthy that the findings of Aitken et al provide strong evidence that tumor size \> 5 cm is one of the strongest predictors of lymph node metastases.[@b18-bcbcr-7-2013-035] Susini et al found tumor localization in the outer quadrants to be a significant independent predictor of axillary lymph node metastases.[@b19-bcbcr-7-2013-035] In our population, we were not able to confirm any impact of tumor localization. The fact that suspicious axillary palpation and presence of metastases affect axillary lymph node status is obvious.

Conclusion
==========

Since pre-surgery axillary nodal staging is determining disease management, ie, SNLB or ALND, axillary ultrasound is a useful add-on tool in the diagnostic armamentarium for breast cancer patients. Tumor size, suspicious axillary palpation, number of affected lymph nodes, and distant metastases increase diagnostic performance of this diagnostic modality.
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ALND

:   axillary lymph node dissection

BMI

:   body mass index

CLIS

:   lobular carcinoma in situ

DCIS

:   ductal carcinoma in situ

npv

:   negative predictive value

ppv

:   positive predictive value

SLNB

:   sentinel lymph node biopsy

![Prediction of nodal status by palpation only vs. palpation and sonography.](bcbcr-7-2013-035f1){#f1-bcbcr-7-2013-035}

###### 

Demography of study population (n = 172).

  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Age \[years\] (Mean ± SD, n = 172)                 58.8 ± 12.9
  Body mass index \[kg/m^2^\] (Mean ± SD, n = 138)   27.2 ± 5.0
  Parity n (%)                                       Nulliparae: 19 (11.1); one child: 52 (30,2); two children: 47 (27.3); ≥three children: 28 (16.3); unknown: 26 (15.1)
  Lactation \[months\] (Mean ± SD, n = 135)          4.2 ± 7.2
  Family history n (%)                               Positive: 48 (28); negative: 113 (66); unknown: 11 (6)
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------

###### 

Tumor characteristics of study population (n = 172).

  ------------------------------------------------------------- ----------------------------------------------------------------------------
  Localization n (%)                                            Right/left upper lateral quadrant: 41 (23.8)/35 (20.4)
  Right/left upper inner quadrant: 22 (12.8)/22 (12.8)          
  Right/left lower inner quadrant: 6 (3.5)/10 (5.8)             
  Right/left lower lateral quadrant: 5 (2.9)/17 (9.9)           
  Right/left central quadrant: 3(1.7)/4 (2.3)                   
  Unknown: 7 (4.1)                                              
  Tumor size \[cm\] (Mean ± SD, n = 156)                        2.13 ± 1.73
  Clinical nodal status n (%)                                   cN+: 54 (31.4); cN0: 118 (68.6)
  Histopathology n (%)                                          Ductal: 103 (59.9); Lobular: 25 (14.5); Other: 43 (25.0); unknown: 1 (0.6)
  Grading n (%)                                                 G1: 8 (4.6); G2: 109 (63.4); G3: 55 (32.0)
  Hormone receptors n (%)                                       ER+/PR+: 121 (70.3)
  ER−/PR−: 27 (15.7)                                            
  ER+/PR−: 13 (7.6)                                             
  ER−/PR+: 5 (2.9)                                              
  Unknown: 6 (3.5)                                              
  Histopathological nodal status n (%)                          pN+: 77 (45); pN0: 95 (55)
  pN0: 95 (55.2); microscopic                                   
  pN1: 6 (3.5); pN1: 40 (23.3); pN2: 10 (5.8); pN3: 21 (12.2)   
  Metastases (pM or cM) n (%)                                   M0: 155 (90.1); M1: 17 (9.9)
  pT n (%)                                                      pT1: 101 (58.7); pT2: 46 (26.7); pT3: 6 (3.5); pT4: 19 (11.1)
  ------------------------------------------------------------- ----------------------------------------------------------------------------

###### 

Impact of clinical and pathological factors on sensitivity and specificity of palpation plus axillary sonography.

  **Subgroup**                    **Difference of sensitivities (*P*-value)**   **Difference of specificities (*P*-value)**
  ------------------------------- --------------------------------------------- ---------------------------------------------
  Age at diagnosis                0.21                                          0.67
  BMI                             0.74                                          0.91
  Tumor localization              0.48                                          0.057
  Tumor size                      0.22                                          **0.04**
  Multicentric cancer             0.65                                          0.28
  Palpable axillary lymph nodes   \<**0.01**                                    \<**0.01**
  No. of affected lymph nodes     \<**0.01**                                    --
  Carcinoma type                  0.41                                          0.63
  Grading                         0.17                                          0.24
  Hormone receptor status         0.44                                          0.13
  HER2/neu                        0.24                                          1.00
  Lymphangiosis carcinomatosa     0.21                                          0.28
  M (0/1) (pM or cM)              **0.04**                                      \<**0.01**

**Note:** Bold numbers indicate statistical significance.

###### 

Factors significantly influencing sensitivity and specificity of the combination of palpation plus axillary ultrasound.

                                **n**   **Sensitivity**   **Specificity**                                         **ppV**   **npV**
  ----------------------------- ------- ----------------- ------------------------------------------------------- --------- ---------
  Tumor size                                                                                                                
    \< 2 cm                     92      0.462             0.939                                                   0.75      0.816
    2.0--2.9 cm                 38      0.667             0.714                                                   0.8       0.556
    3.0--3.9 cm                 10      0.375             1                                                       1         0.286
    4.0--4.9 cm                 5       1                 0.5                                                     0.75      1
    ≥ 5 cm                      11      0.62              1                                                       1         0.5
    *P*-value                           0.22              **0.04**                                                          
  Axillary palpation                                                                                                        
    Positive                    29      0.96              0.40                                                    0.88      0.67
    Negative                    142     0.40              0.93                                                    0.78      0.73
    *P*-value                           \<**0.01**        \<**0.01**                                                        
  No. of affected lymph nodes                                                                                               
    0                           96      0                 0.91                                                    0         0.99
    1--3                        45      0.42              --                                                      1         0
    4--9                        10      0.7               --                                                      1         0
    ≥ 10                        19      0.9               --                                                      1         0
    *P*-value                           \<**0.01**        --                                                                
  M (0/1)                                                                                                                   
    M1 (pM1 or cM1)             17      0.81              0.00[\*](#tfn3-bcbcr-7-2013-035){ref-type="table-fn"}   0.93      0.00
    M0                          155     0.53              0.91                                                    0.80      0.75
    *P*-value                           **0.04**          \<**0.01**                                                        

**Notes:**

All women with metastases at first diagnosis had positive axillary lymph nodes. Thus, the number of correct negative results and the value for specificity were zero. Bold numbers indicate statistical significance.
